MTA-SZTE Research Group on Artificial Intelligence
SZTE Publicatio Repozitórium - SZTE - Repository of PublicationsNot a member yet
32192 research outputs found
Sort by
II. (VII.) Jakab Anglia, Skócia és Írország királya, a hit védelmezője: Egy bigott uralkodó és kora
Get PDF
Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. 72-Week Results from the BALATON and COMINO Trials
Get PDFTo assess the efficacy, durability, and safety of dual angiopoietin-2/VEGF inhibition with faricimab dosed per a modified treat-and-extend-based regimen in patients with retinal vein occlusion.Single-arm treatment period after a randomized, double-masked, active comparator-controlled period in the phase III BALATON/COMINO (NCT04740905/NCT04740931) trials.Patients with treatment-naïve foveal center-involved macular edema due to branch (BALATON; N = 553) or central/hemiretinal (COMINO; N = 729) retinal vein occlusion.Patients randomized to faricimab 6.0 mg every 4 weeks (Q4W) or aflibercept 2.0 mg Q4W up to week 20 received faricimab 6.0 mg dosed per a modified treat-and-extend-based regimen from week 24 to 72. The dosing frequency was adjusted from Q4W to Q16W based on changes in central subfield thickness (CST) and best-corrected visual acuity.Change from baseline through week 72 in best-corrected visual acuity and CST; durability and safety through week 72.Visual acuity gains and CST reductions achieved at week 24 were maintained through week 72. Adjusted mean best-corrected visual acuity (95.03% confidence interval [CI]) changes from baseline averaged over weeks 64, 68, and 72 in the prior faricimab Q4W and prior aflibercept Q4W arms were +18.1 letters (16.9-19.4) and +18.8 letters (17.5-20.0), respectively, in BALATON and +16.9 letters (15.2-18.6) and +17.1 letters (15.4-18.8), respectively, in COMINO. Adjusted mean (95.03% CI) CST changes from baseline averaged over weeks 64, 68, and 72 in the prior faricimab Q4W and prior aflibercept Q4W arms were -310.9 μm (-315.6 to -306.3) and -307.0 μm (-311.7 to -302.3), respectively, in BALATON and -465.9 μm (-472.5 to -459.3) and -460.6 μm (-467.2 to -453.9), respectively, in COMINO. In the prior faricimab Q4W and prior aflibercept Q4W arms, 64.1% and 56.9% of patients from BALATON and 45.5% and 50.1% from COMINO, respectively, were on ≥Q12W dosing at week 68. Faricimab continued to be well tolerated from weeks 24 to 72; the safety profile was consistent with that established for diabetic macular edema and neovascular age-related macular degeneration.These findings support the sustained efficacy and safety of faricimab in patients with macular edema due to retinal vein occlusion up to 72 weeks, with the potential for reduced treatment burden due to response durability.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article
Az SWT® IPL technológia az esztétikai bőrgyógyászatban [Use of SWT® IPL technology in Aesthetic Dermatology]
Get PDFAlthough Intense Pulsed Light (IPL) devices emit a broad spectrum of light, which has different properties than laser light, modern, high quality IPL devices, when used with appropriate settings and indications, can achieve treatment outcomes comparable to laser treatments. Since its approval several innovations have been made in IPL technology. SWT® Dual-Filter Technology not only cuts off lower wavelengths, but also uses a water filter to remove wavelengths longer than 950 nm. This reduces light absorption by water in the skin, resulting in less heat generation for a less painful and safer treatment. The aim of this article is to summarize the common indications and advantages of SWT® IPL technology, illustrated with the author’s clinical results
The Intersection of Justice and European Union Integration : War Crimes Adjudication in Kosovo
Get PDFA kínai házasságjog alakulása a 20-21. században a jogi sinológia vizsgálati módszerének tükrében
Get PDF
Fluorescent gold nanoclusters stabilized by lysozyme: Synthesis and deposition kinetics on silica substrates
Get PDF
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease : An International Real-Life Retrospective Multicentre Cohort Study
Get PDFPerianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose-derived mesenchymal stem cell treatment are contradicting, and real-world evidence is lacking.To examine the usability of darvadstrocel therapy in managing perianal CD.We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression.Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported.Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success